Pfizer Inc (PFE) 29.23 $PFE
Market Maker Surveillance Report. ANR, PFE, AMAT, XOM, EMC, QQQ, Bearishly Biased Price Friction For Tuesday, September 9th 2014
M2 - 1 hr 49 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4670 companies with "abnormal" market making, 1404 companies with positive Friction Factors and 3746 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Alpha Natural Resources Inc (NYSE:ANR), Pfizer Inc (NYSE
FE), APPLIED MATERIALS, INC. (NASDAQ:AMAT), EXXON MOBIL CORPORATION (NYSE:XOM), EMC Corp (NYSE:EMC), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Most active New York Stock Exchange-traded stocks
AP - Tue Sep 09, 7:16PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Sep 09, 7:15PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Same-sex marriage heading for Supreme Court vote?
By MARK SHERMAN - AP - Tue Sep 09, 2:17PM CDT
WASHINGTON (AP) — Both sides in the gay marriage debate agree on one thing: It's time for the Supreme Court to settle the matter.
Midday Glance: Pharmaceuticals companies
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Sep 09, 9:44AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Pfizer (PFE) Approaches New Downside Target of $29.10
Comtex SmarTrend(R) - Tue Sep 09, 9:00AM CDT
Shares of Pfizer (NYSE FE) have bearishly opened below the pivot of $29.45 today and have reached the first support level of $29.25. Should the shares continue to fall, the support pivots of $29.10 and $28.75 will be of interest.
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
Polycystic Kidney Disease Therapeutics Pipeline Review, H2 2014 - 21 Drug Profiles from 11 Companies
M2 - Tue Sep 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8mqd9t/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Plexxikon Inc. - Ipsen S.A. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Company, LLC - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Corporation, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 (ascorbic acid menadione) - MSDC-0160 - MSDC-0602 - EC-0371 - Small Molecule to Inhibit CKD for Polycystic Kidney Disease - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Small Molecules to Activate AMPK for Polycystic Kidney Disease - Small Molecule to Inhibit EnaC for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Small Molecule for Polycystic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - pyrimethamine For more information visit http://www.researchandmarkets.com/research/8m...tic_kidney
Glaxo Announces EU Nod for Single-Pill HIV Drug Triumeq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:25PM CDT
ViiV Healthcare's Triumeq approved for the treatment of HIV-1 infection in patients above 12 years and weighing at least 40kg.
Is It Time to Buy Actavis plc Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 1:15PM CDT
By all available metrics, the healthcare sector has been performing admirably so far this year. Despite a weak second quarter, most healthcare stocks have seen their share prices climb by double digits for a third straight year. While the sector...
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
Novartis Offers Healthy Gains at a Bargain Stock Price
at The Street - Fri Sep 05, 5:30AM CDT
The company has a potential life-saving catalyst in its portfolio, too.
Market Maker Surveillance Report. PFE, TWX, CSCO, MDT, DEPO, QQQ, Bearishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE FE), TIME WARNER INC. (NYSE:TWX), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Medtronic Inc (NYSE:MDT), Depomed Inc (NASDAQ
EPO), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Surveillance Report. ANR, PFE, AMAT, XOM, EMC, QQQ, Bearishly Biased Price Friction For Tuesday, September 9th 2014
M2 - 1 hr 49 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4670 companies with "abnormal" market making, 1404 companies with positive Friction Factors and 3746 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Alpha Natural Resources Inc (NYSE:ANR), Pfizer Inc (NYSE
FE), APPLIED MATERIALS, INC. (NASDAQ:AMAT), EXXON MOBIL CORPORATION (NYSE:XOM), EMC Corp (NYSE:EMC), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Most active New York Stock Exchange-traded stocks
AP - Tue Sep 09, 7:16PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Sep 09, 7:15PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Same-sex marriage heading for Supreme Court vote?
By MARK SHERMAN - AP - Tue Sep 09, 2:17PM CDT
WASHINGTON (AP) — Both sides in the gay marriage debate agree on one thing: It's time for the Supreme Court to settle the matter.
Midday Glance: Pharmaceuticals companies
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Sep 09, 9:44AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Pfizer (PFE) Approaches New Downside Target of $29.10
Comtex SmarTrend(R) - Tue Sep 09, 9:00AM CDT
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $29.45 today and have reached the first support level of $29.25. Should the shares continue to fall, the support pivots of $29.10 and $28.75 will be of interest. Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
Polycystic Kidney Disease Therapeutics Pipeline Review, H2 2014 - 21 Drug Profiles from 11 Companies
M2 - Tue Sep 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8mqd9t/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Plexxikon Inc. - Ipsen S.A. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Company, LLC - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Corporation, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 (ascorbic acid menadione) - MSDC-0160 - MSDC-0602 - EC-0371 - Small Molecule to Inhibit CKD for Polycystic Kidney Disease - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Small Molecules to Activate AMPK for Polycystic Kidney Disease - Small Molecule to Inhibit EnaC for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Small Molecule for Polycystic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - pyrimethamine For more information visit http://www.researchandmarkets.com/research/8m...tic_kidney
Glaxo Announces EU Nod for Single-Pill HIV Drug Triumeq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:25PM CDT
ViiV Healthcare's Triumeq approved for the treatment of HIV-1 infection in patients above 12 years and weighing at least 40kg.
Is It Time to Buy Actavis plc Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 1:15PM CDT
By all available metrics, the healthcare sector has been performing admirably so far this year. Despite a weak second quarter, most healthcare stocks have seen their share prices climb by double digits for a third straight year. While the sector...
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
Novartis Offers Healthy Gains at a Bargain Stock Price
at The Street - Fri Sep 05, 5:30AM CDT
The company has a potential life-saving catalyst in its portfolio, too.
Market Maker Surveillance Report. PFE, TWX, CSCO, MDT, DEPO, QQQ, Bearishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE
FE), TIME WARNER INC. (NYSE:TWX), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Medtronic Inc (NYSE:MDT), Depomed Inc (NASDAQ EPO), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . 
